Maximum quantity allowed is 999
Please select the quantity
CAS RN: 117570-53-3 | Product Number: D5235
Vadimezan
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- DMXAA
- 2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic Acid
- ASA-404
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days |
|---|---|---|---|
| 50MG |
₩238,700
|
10 | Contact Us |
| 250MG |
₩764,100
|
4 | 17 |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
| Product Number | D5235 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__7H__1__4O__4 = 282.30 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 250MG-Glass Bottle with Plastic Insert (View image), 50MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 117570-53-3 |
| Reaxys Registry Number | 4262852 |
| PubChem Substance ID | 468591309 |
| MDL Number | MFCD00870555 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
Properties (reference)
| Melting Point | 264 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | ZD5536200 |
Transport Information:
| H.S.code* | 2932.99-000 |
Application
DMXAA: A Compound Used as a Tumor Vascular Disputing Agent and an Immune Adjuvant
DMXAA (other names: vadimezan, ASA404) is a tumor vascular disputing agent (VDA) that can cause a specific and irreversible destruction of established tumor vessels. Reportedly, DMXAA induces apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. DMXAA showed anti-tumor effects against solid tumors in mouse models but subsequently failed in human clinical trials in 2010.
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)
References
- An overview on Vadimezan (DMXAA): The vascular disrupting agent (a review)
- The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant
- Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.